Todos os estudos
RecrutamentoConfirmatório terapêutico (Fase III)Intervencionista

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or II A Pharmacokinetic Subtrial in Adolescent Patients with Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial

This research is an ongoing study to see how safe a new medicine, KVD900, is when taken over a longer period. KVD900 is a tablet designed to treat sudden swelling attacks in people who have a condition called Hereditary Angioedema (HAE) Type 1 or 2. The study involves both adults and teenagers. For teenagers specifically, the researchers are also looking at how their bodies process the medicine. The main goal is to keep an eye on any side effects and understand how patients are generally doing while taking KVD900 for their HAE attacks.

Em resumo

Status
Recrutamento
Fase
Confirmatório terapêutico (Fase III)
Patrocinador
Kalvista Pharmaceuticals Limited
Meta de inscrição
75
Iniciar
26 Feb 2024

Sobre o que é este estudo?

This study is about a medicine called KVD900, which is being tested for people who have a condition called Hereditary Angioedema (HAE) Type 1 or 2. HAE is a rare genetic condition that causes sudden and unpredictable swelling in different parts of the body, such as the face, hands, feet, tummy, or airways, which can be very painful and sometimes dangerous.

The medicine, KVD900, is an oral tablet, meaning you take it by mouth. It's designed to be used "on-demand" – so when you feel an HAE attack starting. This study is an "open-label extension trial," which means that everyone taking part knows they are receiving the actual study medicine, KVD900. It's an extension because it allows people who have been in previous studies with KVD900 to continue taking it for a longer time.

The main purpose of this study is to closely monitor the safety of KVD900 over a longer period. The researchers want to see if there are any side effects, how often they occur, and if anyone needs to stop taking the medicine because of them. They will also be checking blood test results and general health signs like blood pressure regularly. For teenagers specifically, there's an additional part of the study (called a "subtrial") to understand how their bodies handle and use the medicine.

Pontos principais

  • This study is testing the long-term safety of KVD900 for HAE Type 1 or 2.
  • KVD900 is a tablet taken at the start of an HAE swelling attack.
  • It's an extension study for people previously in KVD900 trials.
  • Researchers will monitor side effects and overall health.
  • Teenagers will have extra checks to see how their bodies handle the medicine.
  • Participation involves regular visits and health assessments.

Quem pode ser elegível?

To be part of this study, you generally need to be an adult, aged 18 years or older. There might be some specific requirements for teenagers due to the additional part of the study focused on how young bodies process the medicine.

Since this is an "extension" study, it means that you would typically have already taken part in an earlier study for KVD900. This helps the researchers continue to gather long-term information on people who are already familiar with the medicine.

Both males and females can take part. The most important health requirement is that you must have been diagnosed with Hereditary Angioedema Type 1 or Type 2. The study team will check your full medical history and current health to make sure it's safe for you to join.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Are you 18 years old or older? (Or a teenager specifically asked to join the adolescent subtrial?)
  2. Have you been diagnosed with Hereditary Angioedema Type 1 or Type 2?
  3. Have you previously taken part in a KVD900 study?
  4. Are you able to attend regular study visits and follow instructions?
  5. Are you willing to take the study medicine as directed?
  6. Are you comfortable with blood tests and physical examinations?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join this study, you would continue to take the study medicine, KVD900, by mouth when you experience an HAE attack. You would have regular check-ups with the study team. These visits will involve various assessments, including physical examinations, blood tests, and checking your vital signs like blood pressure and heart rate. These checks help the researchers understand how you are responding to the medicine and if there are any safety concerns.

You would also be asked to keep track of your HAE attacks and how well the medicine works for you. The study will look at how quickly your symptoms improve after taking KVD900. The total duration of your participation would depend on the study plan, but because it's an extension study, it's designed to gather long-term information.

Riscos e benefícios potenciais

Taking part in this study may offer potential benefits, such as continued access to a new on-demand treatment for your HAE attacks that might effectively relieve your symptoms. However, like all medicines, KVD900 may have potential side effects. These could include common side effects, or possibly more serious but rare ones, and the study aims to carefully monitor these. You will be told about all known risks before you decide to join. It is very important to remember that participating in any study is completely voluntary, and you have the right to withdraw at any time, for any reason, without affecting your regular medical care.

Locations (13)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Eslováquia
  • —
    Não verificado
    Países Baixos
  • —
    Não verificado
    Itália
  • —
    Não verificado
    Bulgária
  • —
    Não verificado
    Hungria
  • —
    Não verificado
    Áustria
  • —
    Não verificado
    Alemanha
  • —
    Não verificado
    Grécia
  • —
    Não verificado
    Polônia
  • —
    Não verificado
    Romênia
  • —
    Não verificado
    França
  • —
    Não verificado
    Espanha

Perguntas frequentes

What is Hereditary Angioedema (HAE)?

HAE is a rare condition that causes sudden swelling in different parts of your body, which can be painful and sometimes serious.

What is KVD900?

KVD900 is an investigational medicine in tablet form, being studied to treat HAE swelling attacks when they happen.

Is this medicine available to everyone?

No, KVD900 is currently a study medicine and is not yet available as a standard treatment.

Why is this an 'extension' study?

It means people who were in earlier KVD900 studies can continue taking the medicine to gather more information on its long-term safety.

Will I know if I'm getting the real medicine?

Yes, this is an 'open-label' study, so everyone involved knows they are receiving KVD900.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "An Open-label Extension Trial to Evaluate the Long-term Safe…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.